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Abstract
Background: Serum magnesium is inversely associated to coronary artery calcification (CAC) in patients with
chronic kidney disease. There is little information on this association in a general healthy population.
Objective: The aim of this study was to examine the cross-sectional association of serum magnesium levels with
CAC.
Methods: We included 1276 Mexican-mestizo subjects (50 % women), aged 30–75 years, free of symptomatic
cardiovascular disease. CAC was quantified by multidetector computed tomography using the method described
by Agatston. Cross-sectional associations of serum magnesium with cardiometabolic factors and subclinical
atherosclerosis defined as a CAC score > 0, were examined in logistic regression models adjusted for age, sex,
education, smoking status, body mass index, systolic blood pressure, physical activity, elevated abdominal visceral
tissue, fasting insulin and glucose, alcohol consumption, menopausal status (women only), low (LDL-C) and high
density lipoprotein cholesterol (HDL-C), triglycerides, diuretic use, type 2 diabetes mellitus (DM2), and family history
of DM2.
Results: After full adjustment, subjects in the highest quartile of serum magnesium had 48 % lower odds of
hypertension (p = 0.028), 69 % lower odds of DM2 (p = 0.003), and 42 % lower odds of CAC score > 0 (p = 0.016)
compared to those with the lowest serum magnesium. The analyses also showed that a 0.17 mg/dL (1SD)
increment in serum magnesium was independently associated with 16 % lower CAC (OR 0.84, 95 % CI 0.724–0.986).
Conclusions: In a sample of Mexican-mestizo subjects, low serum magnesium was independently associated to
higher prevalence not only of hypertension and DM2, but also to coronary artery calcification, which is a marker of
atherosclerosis and a predictor of cardiovascular morbidity and mortality.
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Introduction
Magnesium plays an important role in many biochem-
ical processes including all ATP transfer reactions.
Magnesium is essential for insulin release by pancreatic
β-cells, and is also and important second messenger for
insulin action [1, 2]. Cross-sectional [3] and longitu-
dinal studies [4, 5] have found a significant inverse as-
sociation between serum magnesium and DM2, insulin
resistance and inflammation. Moreover, magnesium is a
natural calcium antagonist [6] and modulates vaso-
motor tone, blood pressure, and peripheral blood flow
[7, 8]. In prospective studies, serum magnesium levels
have been inversely associated with the incidence of
hypertension [9] and coronary heart disease (CHD)
[10]. Increased carotid intima-media thickness (CIMT)
and coronary artery calcification (CAC) are both
markers of subclinical atherosclerosis, and are also pre-
dictors of cardiovascular disease (CVD) morbidity and
mortality independently of traditional CVD risk factors
[11–13]. Inverse associations between serum magne-
sium and CIMT have been reported [3, 14]. However,
conflicting results have been found in the two studies
investigating the association of dietary magnesium and
CAC [15, 16]. Moreover, a negative association between
serum magnesium and vascular calcification has been ob-
served in patients with chronic kidney disease [17]. The
only observational study that has examined this associ-
ation in a population-based study reported that low serum
magnesium level is associated with CAC in Koreans sub-
jects [18]. However, it is known that CAC prevalence and
amount are heavily influenced by ethnicity [19, 20]. There-
fore, in the present study we assessed the cross-sectional
association of serum magnesium concentrations with cor-
onary artery calcification in Mexican-mestizo subjects




The study population included participants of the
Genetics of Atherosclerotic Disease (GEA) study. The
GEA study was designed to examine the genomic
bases of CHD and assess relationships between trad-
itional and emerging risk factors with clinical and sub-
clinical atherosclerotic vascular diseases in an adult
Mexican-mestizo population [21]. Briefly, a conveni-
ence sample of 1200 CHD patients and 1500 control
subjects aged 30–75 years was recruited from resi-
dents in Mexico City. Patients with established prema-
ture CHD were selected from the outpatient clinic of
the National Institute of Cardiology. Volunteer control
participants with a negative family history of prema-
ture CHD and no personal history of cardiovascular
disease were recruited from blood bank donors, and
through brochures posted in Social Services centers.
Coronary patients and control subjects with a history
of renal, liver, thyroid, or malignant disease, as well as
those on treatment with corticosteroids, were ex-
cluded. The GEA study was approved by the Institutional
Review Board of the National Institute of Cardiology and
conducted according to the Declaration of Helsinki.
Written informed consent was obtained from all
participants.
This study is a cross-sectional analysis of the baseline
measurements of 1500 control subjects included in the
GEA study. The participants answered structured ques-
tionnaires that provide detailed information regarding
family history, demographics, diet, physical activity, medi-
cations, smoking, and alcohol intake. We excluded all sub-
jects with missing CAC (n = 25), missing physical activity
data (n = 111), missing dietary data (n = 45), missing insu-
lin (n = 1) and magnesium sampling (n = 42). The final
study population included in the analysis comprised 1276
subjects. Systolic and diastolic blood pressures were
measured after rest for at least 10 min, and the average
of the second and third measurements was recorded
for analyses. Hypertension was defined as systolic blood
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90
mmHg or the current use of antihypertensive medica-
tion. Height, weight, and waist circumference were
measured and BMI was calculated as weight in kilograms
divided by height in meters squared. The metabolic syn-
drome (MS) was defined using the criteria from the
American Heart Association/National Heart, Lung, and
Blood Institute scientific statement on the MS [22], except
for central obesity that was considered when waist cir-
cumference was > 90 cm in men and > 80 cm in women
[23]. Type 2 diabetes mellitus (DM2) was defined by the
American Diabetes Association criteria [24], reported
glucose-lowering treatment or previous DM2 diagnosis by
a physician. Family history of DM2 was defined as either
mother or father having DM2. Insulin resistance was
estimated using the homeostasis model assessment
(HOMA-IR). Insulin resistance was defined as HOMA-IR
values ≥ 75th percentile (3.66 in women and 3.38 in men).
These cutoff points were obtained from a GEA study
sample of 131 men and 185 women without obesity
and with normal of blood pressure, fasting glucose and
lipids measurements.
Biochemical analyses
Venous blood samples were collected from subjects after
a 12 h fast. Plasma glucose, total cholesterol, triglycerides,
HDL-C, apolipoprotein A (apo A), apolipoprotein B (apo
B), creatinine, uric acid, aspartate aminotransferase (AST),
and alanine aminotransferase (ALT), were measured in
fresh samples, using standardized enzymatic procedures
in a Hitachi 902 analyzer (Hitachi Ltd,Tokio, Japan).
Posadas-Sánchez et al. Nutrition Journal  (2016) 15:22 Page 2 of 7
Accuracy and precision of lipid measurements in our
laboratory are under periodic surveillance by the Centers
for Disease Control and Prevention service (Atlanta, GA,
USA). LDL-C was estimated using the DeLong et al. for-
mula [25]. Total high-sensitivity C-reactive protein (hs-
CRP) levels were determined by immunonephelometry on
a BN Pro Spec nephelometer (Dade Behring Marburg
GmbH, Germany). Interassay coefficient of variation (CV)
values were <6 % for all of these assays. Serum total
adiponectin was determined by ELISA (R&D Systems,
Minneapolis, USA) Quantine kit. The intra- and inter-
assay CV were < 10 %. Plasma insulin concentrations
were determined by a radioimmunoassay (Millipore;
RIA Kit, Cat. No. HI-14 K, MO, USA) the intra- and
interassay CV values were 2.1 and 6.8 %, respectively.
Serum magnesium levels were measured by using the
direct xylidyl blue complex method in a COBAS C311
automated chemistry analyzer (Roche diagnotics
GmbH, Germany). The intra and interassay coefficient
of variation were ≤1.0 %.
Computed tomography study
Visceral adipose tissue (VAT), subcutaneous fat, liver
and spleen attenuation, and coronary artery calcium
were quantified by computed tomography in each par-
ticipant. Computed tomography of the chest and abdo-
men were performed using a 64-channel multidetector
helical computed tomography system (Somatom Cardiac
Sensation, 64, Forcheim, Germany) and interpreted by
experienced radiologists. Scans were read to assess and
quantify the following: i) total abdominal, subcutaneous,
and VAT areas as described by Kvist et al. [26]; ii) liver
to spleen attenuation ratio (L:SAR) as described by
Longo et al. [27]; and iii) CAC score using the Agatston
method [28]. Subclinical atherosclerosis was defined as
the presence of a CAC score > 0.0 and hepatic steatosis
as L:SAR ≤1.0 [29].
Data analysis
Data are expressed as mean ± S.D., median [interquartile
range] for continuous variables, or as proportions for
categorical variables. Serum magnesium concentrations
were categorized by quartile distribution with the lowest
quartile serving as the reference. Differences across
quartiles were assessed with ANOVA or Kruskal-Wallis
test for continuous variables, and Chi square test for cat-
egorical variables. Multivariate logistic regression ana-
lysis was used to evaluate the association between each
S.D. increase in serum magnesium concentrations with
coronary risk factors and CAC. For coronary risk factors,
the forced-entry logistic regression analyses were ad-
justed for age, sex, education, smoking status, elevated
abdominal visceral adipose tissue, body mass index, sys-
tolic blood pressure, low and high density lipoprotein
cholesterol, triglycerides, fasting insulin and glucose,
physical activity, alcohol consumption, menopausal sta-
tus (women only) and diuretic use. For CAC, three
forced-entry logistic regression models were constructed:
an unadjusted model; a model adjusted for age, sex, edu-
cation, smoking status, body mass index, systolic blood
pressure, and physical activity (model 1); a regression
model further adjusted for elevated abdominal visceral
adipose tissue, fasting insulin and glucose, and alcohol
consumption (model 2); and, finally, a regression model
adjusted for the variables included in model 2 plus
menopausal status (women only), low and high density
lipoprotein cholesterol, triglycerides, diuretic use, DM2
and family history of DM2 (model 3). P values <0.05
were considered statistically significant. All statistical
procedures were performed using the SPSS software
(SPSS version 15.0, Inc.).
Results
This study included 1276 subjects (640 women, 636
men) with a mean age 54 ± 9 (SD) years, with no family
history of premature CHD or CVD symptoms. Com-
pared to women, men had a higher prevalence of high
blood pressure (11.9 % vs 7.3 %, p = 0.006), insulin re-
sistance (61.8 % vs 54.7 %, p = 0.011) and metabolic syn-
drome (49.2 % vs 40.9 %, p = 0.003). The prevalence of
current smoking (25.1 % of men and 18.9 % of women)
and type 2 diabetes mellitus (15 % of men and 13.4 % of
women) were not significantly different between gen-
ders. Two thirds of women (66.4 %) were postmeno-
pausal. The mean serum magnesium concentration in
the whole population was 2.06 ± 0.17 (SD) mg/dl, and
was slightly higher in men than in women (2.07 ± 0.16
(SD) mg/dl vs 2.06 ± 0.18 (SD) mg/dl, p = 0.09). The
overall prevalence of CAC score > 0 was 27.2 %. (41.5 %
of men and 13 % of women, p < 0.001).
Table 1 shows clinical, computed tomography and la-
boratory characteristics of participants according to
serum magnesium quartiles. Systolic blood pressure,
fasting glucose, HOMA-IR and C reactive protein were
inversely associated with serum magnesium levels. High
serum magnesium levels were also associated with lower
prevalence of hypertension, DM2, insulin resistance,
metabolic syndrome, and CAC score >0. A similar non-
significant trend was observed for body mass index and
fasting insulin levels. In contrast, total and LDL-
cholesterol and apolipoprotein B were greater with in-
creasing serum magnesium levels. Visceral adipose tissue,
triglycerides, and adiponectin were not associated with
serum magnesium levels.
Multivariate logistic regression analyses were performed
to examine the associations of serum magnesium levels
with cardiometabolic risk factors and CAC score >0
(Table 2). After adjustment for several confounding
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Table 1 Characteristics of 1276 GEA study participants according to serum magnesium quartiles
Q1<1.97 mg/dl Q2≥1.97 to <2.07 mg/dl Q3≥2.07 to <2.18 mg/dl Q4≥2.18 mg/dl P*
N 326 304 338 308
Serum magnesium (mg/dl) 1.90 [1.83–1.94] 2.03 [2.00–2.05] 2.11 [2.09–2.14] 2.24 [2.20–2.29] <0.001
Dietary magnesium (mg) 351 [290–410] 344 [292–421] 356 [289–424] 358 [293–422] 0.692
Male (%) 50 49.3 51.2 49 0.949
Age (years) 54 ± 10 53 ± 10 54 ± 9 55 ± 9 0.079
Body mass index (kg/cm2) 28.8 ± 4.2 28.4 ± 4.2 28.0 ± 4.0 28.1 ± 3.8 0.056
Visceral adipose tissue (cm2) 157 [112–211] 148 [112–190] 150 [109–194] 148 [115–193] 0.196
Systolic blood pressure (mmHg) 118 [108–130] 113 [103–125] 114 [106–123] 113 [103–123] <0.001
Glucose (mg/dl) 95 [87–125] 91 [85–99] 89 [83–96] 89 [84–96] <0.001
Insulin (μU/ml) 18.1 [13.2–24.9] 18.2 [12.6–24.7] 16.7 [12.4–22.8] 16.4 [12.3–22.4] 0.067
HOMA-IR 4.9 [3.0–7.5] 4.2 [2.8–5.7] 3.7 [2.6–5.4] 3.6 [2.6–5.1] <0.001
Cholesterol
Total (mg/dl) 190 ± 36 190 ± 37 193 ± 37 198 ± 37a,b 0.015
LDL (mg/dl) 116 ± 32 117 ± 33 117 ± 32 123 ± 33a,b,c 0.009
HDL (mg/dl) 45.7 ± 13.2 45.1 ± 13.3 47.8 ± 14.1 45.6 ± 13.0 0.065
Triglycerides (mg/dl) 148 [114–200] 152 [113–202] 145 [106–209] 153 [116–204] 0.844
Apolipoprotein B (mg/dl) 92 [74–112] 93 [75–111] 95 [79–115] 103 [85–122] <0.001
Apolipoprotein A (mg/dl) 133 [114–154] 131 [111–152] 134 [117–158] 135 [117–155] 0.095
Adiponectin (μg/ml) 8.0 [4.8–11.8] 7.6 [5.0–12.1] 8.1 [5.2–13.1] 7.8 [5.0–12.2] 0.915
hsCRP (mg/l) 1.8 [0.9–3.6] 1.5 [0.8–3.3] 1.4 [0.7–2.9] 1.4 [0.8–3.0] 0.018
Current smoking (%) 21 23 23 21 0.765
Physical activity 7.75 [6.88–8.88] 7.88 [6.75–8.75] 7.88 [7.13–8.75] 7.75 [7.00–8.63] 0.256
Menopausal women (%) 62 62.3 64.8 76.6 0.018
Hypertension (%) 14 8 8 8 0.009
Type 2 diabetes mellitus (%) 34 10 8 5 <0.001
Insulin resistance (%) 66 63 53 51 <0.001
Metabolic syndrome (%) 54 44 41 41 0.003
CAC score >0 (%) 35 24 26 24 0.002
Values are expressed as mean ± SD, median [IR, interquartile range] or percentages. HOMA-IR Homeostasis model assessment insulin resistance, LDL Low density
lipoprotein, HDL High density lipoprotein, hsCRP High sensitive C reactive protein
*for ANOVA, Kruskal-Wallis or Chi square test. P <0.05 aversus Q1, bversus Q2, cversus Q3
Table 2 Association of serum magnesium levels with cardiometabolic risk factors and subclinical atherosclerosis
Q1 Q2 Q3 Q4
Odds ratio [CI 95 %] Odds ratio [CI 95 %] Odds ratio [CI 95 %]
Hypertension 1 0.52 [0.295–0.917] 0.56 [0.323–0.961] 0.52 [0.294–0.931]
Insulin resistance 1 1.26 [0.891–1.940] 0.96 [0.632–1.467] 1.02 [0.694–1.506]
Metabolic syndrome 1 1.04 [0.715–1.512] 1.01 [0.696–1.467] 1.02 [0.964–1.506]
Type 2 diabetes mellitus 1 0.42 [0.199–0.886] 0.34 [0.161–0.705] 0.31 [0.143–0.672]
CAC score >0 1 0.68 [0.436–1.070] 0.78 [0.507–1.197] 0.58 [0.374–0.915]
Data are expressed as odds ratios and 95 % confidence interval (CI) as assessed by multivariate logistic regression analyses. Other covariates included in the
multivariable regression model, along with serum magnesium were: age, sex, education, smoking status, elevated abdominal visceral adipose tissue, body mass
index, systolic blood pressure, low and high density lipoprotein cholesterol, triglycerides, fasting insulin and glucose, physical activity, alcohol consumption,
menopausal status (women only), family history of type 2 diabetes mellitus, type 2 diabetes mellitus and diuretic use
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factors, individuals with the highest serum magnesium
levels (fourth quartile) had 48 % lower odds lower odds of
hypertension (p = 0.028), 69 % lower odds of DM2 (p =
0.003), and 42 % lower odds of CAC score > 0 (p = 0.016)
as compared to those in the lowest quartile.
Associations of a 1SD (0.17 mg/dL) increment in
serum magnesium levels with hypertension, insulin re-
sistance, metabolic syndrome, and DM2 are described in
Table 3. Variables included in the multivariable model
were age, sex, education, smoking status, elevated ab-
dominal visceral adipose tissue, body mass index, sys-
tolic blood pressure, LDL-C, HDL-C, triglycerides,
fasting insulin and glucose, physical activity, alcohol con-
sumption, menopausal status (women only) and diuretic
use. Higher serum magnesium was associated with 19 %
lower prevalence of hypertension and 38 % lower preva-
lence of DM2 per each 1 SD increment in magnesium
concentration.
In addition, regression models were used to test the
association between CAC and serum magnesium levels
as a continuous variable. A 0.17 mg/dl (1SD) increment
in serum magnesium concentration was associated with
16 % lower coronary artery calcification (odds ratio 0.84;
95 % confidence intervals (CI) 0.741–0.953, p = 0.007) in
the unadjusted model. This association proved to be in-
dependent of age, sex, education, smoking status, body
mass index, systolic blood pressure, and physical activity
(model 1; odds ratio 0.84; CI 0.724–0.964, p = 0.014). A
regression model further adjusted for elevated abdom-
inal visceral adipose tissue, fasting insulin and glucose,
and alcohol consumption (model 2; odds ratio 0.86; CI
0.737–0.995, p = 0.043) continued to show a significant
independent association between serum magnesium
concentrations and CAC. Finally, after a full adjustment
(model 2 plus menopausal status -women only-, low and
high density lipoprotein cholesterol, triglycerides, diur-
etic use, DM2 and family history of DM2), a 0.17 mg/dL
(1SD) increment in serum magnesium concentration
remained significantly associated with 16 % lower
coronary artery calcification (odds ratio 0.84; 95 % confi-
dence interval (CI) 0.724–0.986, p = 0.033).
Discussion
We report here an inverse association between serum
magnesium levels and the prevalence of CAC score >0
in a Mexican-mestizo population with no family history
of premature CHD or clinical signs or symptoms of
CVD. This association remained significant after adjust-
ment for a range of confounding factors, including age,
sex, education, smoking status, visceral adipose tissue,
body mass index, systolic blood pressure, low and high
density lipoprotein cholesterol, triglycerides, fasting in-
sulin and glucose, physical activity, alcohol consumption,
menopausal status (women only), diuretic use, DM2,
and family history of DM2. Serum magnesium levels
were also independently associated with a lower risk
hypertension and DM2. The latter associations are con-
sistent with previous reports showing that both conditions
are frequently associated with a magnesium deficient state
as assessed by decreased circulating concentrations of
serum total or ionized magnesium [4, 9, 30, 31].
In regard to the association of magnesium with subclin-
ical atherosclerosis, only two population-based epidemio-
logic studies have examined the relation of magnesium
intake with coronary artery calcification. The first study
was conducted in 5281 MESA (the Multi-Ethnic Study of
Atherosclerosis) participants aged 45–84 years and free of
clinically apparent CVD, reporting no association between
magnesium intake and CAC [16]. The more recent study
included 2695 offspring or third generation Framing
Heart Study participants free of CVD and reported that
higher magnesium intake was associated with lower
levels of CAC [15].
Although an association between serum magnesium
levels and CAC has been reported in patients with
chronic kidney disease [20], to date, only one cross-
sectional analysis has examined serum magnesium levels
in relation to CAC, in large number of Korean individ-
uals without cardiovascular disease participating in a
health examination program [18]. After adjusting for po-
tential confounders, a significant inverse association be-
tween CAC and serum magnesium was observed, which
is consistent with the findings of the present study. In
agreement with these investigations, two decades ago
the Atherosclerosis Risk in Communities Study reported
an inverse association between serum magnesium and
carotid intima-media thickness (CIMT) [3]. More re-
cently, in a population-based study, Hashimoto et. al. re-
ported that low serum magnesium levels were not
only significantly and independently associated with
greater CIMT, but also with the presence of atheroscler-
otic plaques [14]. Increased CIMT is also a marker of
atherosclerotic disease, and like CAC, is and
Table 3 Associations of serum magnesium concentrations with
coronary risk factors
Odds ratio P
Hypertension 0.81 [0.673–0.985] 0.034
Insulin resistance 0.89 [0.763–1.044] 0.155
Metabolic syndrome 1.03 [0.891–1.189] 0.694
Type 2 diabetes mellitus 0.62 [0.489–0.786] <0.001
Odds ratios are expressed in terms of per SD 0.17 mg/dl increase in serum
magnesium levels
Multivariate logistic regression analyses adjusted for age, sex, education,
smoking status, elevated abdominal visceral adipose tissue, body mass index,
systolic blood pressure, low and high density lipoprotein cholesterol,
triglycerides, fasting insulin and glucose, physical activity, alcohol
consumption, menopausal status (women only) and diuretic use
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independent predictor of cardiovascular morbidity and
mortality [11, 12]. Collectively, the results of this and
other studies [3, 14, 15, 18] suggest independent associa-
tions between reduced magnesium dietary intake or low
serum magnesium levels with subclinical atherosclerosis
defined either as increased CIMT or as coronary artery
calcification.
To date, the underlying mechanisms responsible for
the associations between serum magnesium and CAC
are incompletely understood. The adverse cardiovascular
risk profile found in subjects with low levels of serum
magnesium (higher prevalence of DM2, hypertension,
insulin resistance, and metabolic syndrome) could ex-
plain the association. However, in our analysis and in the
report of Lee et.al. [18], the associations between low
magnesium and coronary artery calcification remained
significant after adjustment for these potential con-
founders. This suggests that additional mechanisms, be-
yond classic cardiovascular and metabolic risk factors,
could be partly responsible. Results from other experi-
mental models support the role of these other mecha-
nisms. Experiments in cultured endothelial cells have
demonstrated that magnesium deficiency promotes a
proatherogenic phenotype [32]. Moreover, dietary mag-
nesium restriction in animal models resulted in reduced
plasma and erythrocyte magnesium levels, which was
accompanied by endothelial dysfunction and systemic
inflammation, well known factors involved in the
atherogenic process. Interestingly, these abnormalities
were reverted by magnesium supplementation [33].
These findings are in line with the beneficial effects of
magnesium on inflammation and endothelial dysfunc-
tion [34], and suggest that this mineral may prevent the
onset and progression of atherosclerosis through mech-
anisms beyond known traditional pathways.
The present study has some limitations. First, the
cross-sectional design does not allow to establish causal
or temporal relationships between serum magnesium
and coronary artery calcification. Second, despite the
comprehensive nature of the data which allowed adjust-
ment for multiple risk factors, the possibility of con-
founding from unknown or unmeasured factors cannot
be completely ruled out. Third, our study population
solely comprised Mexican-mestizo subjects, and thus
our findings may not apply to populations of other eth-
nic backgrounds.
Conclusion
The results of this study strongly suggest that lower
serum magnesium levels are associated with coronary ar-
tery calcification in Mexican subjects free of clinically
apparent cardiovascular disease. Confirmation of these
results in other populations is required. Additional pro-
spective studies are also needed to determine if
hypomagnesaemia predicts the development and pro-
gression of coronary atherosclerosis.
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